-
2024-516219-25-00
5
2025-03-25
psoriatic arthritis
-
2023-509234-19-00
4
2025-03-03
Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-507778-42-00
4
2023-03-08
Non-Small Cell Lung Cancer II, III
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-520322-11-00
4
2025-09-29
Type 2 Diabetes Mellitus (T2D)
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2024-515672-12-00
5
2025-05-27
Moderate to Severe Genital Psoriasis
-
2024-515772-12-00
4
2025-04-18
Lung neoplasm malignant (Stage IV Non-small cell lung cancer)
-
2024-513210-36-00
5
2025-04-04
Chronic Spontaneous Urticaria
-
2023-509239-19-00
5
2025-04-03
Active Psoriatic Arthritis
-
2023-505739-12-01
5
2024-09-30
Chronic Inducible Urticaria (CINDU)
-
2023-508630-34-00
5
2024-05-28
Overweight
-
2022-502518-98-00
5
2024-04-26
nonsegmental vitiligo
-
2023-505120-59-00
5
2023-12-19
Moderate to Severe Plaque Psoriasis
-
2023-505122-34-00
5
2023-12-05
Plaque Psoriasis
-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2022-502578-18-00
11
2023-11-07
Rheumatoid Arthritis
-
2022-500802-16-00
5
2023-11-01
Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung